Travoprost patient responses revealed
A recent study was unable to conclude whether intraocular penetration of travoprost 0.004% was affected by central corneal thickness (CCR), potentially explaining differences in patient response to the drug.
A recent study was unable to conclude whether intraocular penetration of travoprost 0.004% was affected by central corneal thickness (CCR), potentially explaining differences in patient response to the drug.
Dr J.M. Martinez-de-la-Casa et al., Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos, Madrid, Spain, observed 64 patients who were scheduled for cataract surgery without any additional ophthalmologic pathology.
Two hours before surgery a single drop of travoprost 0.004% was administered in the eye due for operation. AL-5848 concentration was determined by extracting a sample of aqueous humour.
They were compared to three patient groups identified by CCT measurements obtained by ultrasound pachymetry. Group 1 had a CCT 574 microns.
The results demonstrated a mean AL-5848 concentration of 3.27±2.03 in group 1, 3.27±2.44 ng/mL in Group II and 2.73±2.15ng/mL in group 3, meaning there were no significant differences between the groups.
The paper, published in the journal Eye can be read here.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
